GSK Projects Oncology Pipeline to Nearly Double in 2025
GSK says its clinical-stage oncology portfolio, currently around 15 assets alongside five approved cancer drugs, is set to nearly double next year. The company attributes the expansion to a recent series of acquisitions and licensing deals.